The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Biomarkers, 2007Validation of CSF Alpha-synuclein as a Biomarker for Parkinson's disease
Objective/Rationale:
Accumulation of alpha-synuclein within certain nerve cells represents one of the hallmarks of classical Parkinson disease. Our team recently discovered that alpha-synuclein levels... -
Biomarkers, 2007Multimodal MRI Markers for Parkinson's Disease
Objective/Rationale:
The assessment of Parkinson’s disease is currently based on clinical symptoms that make an accurate diagnosis challenging, especially early on, when subtle impairment of movement... -
Biomarkers, 2007Isoforms of Alpha-synuclein as Biomarkers for Diagnosis and Progression of Parkinson's Disease
Objective/Rationale:
Alpha-synuclein is involved in the development and progression of Parkinson’s disease unequivocally. Our preliminary data has suggested that there were several alpha-synuclein... -
LEAPS, 2007Therapeutic Development of siRNA Targeting Alpha-Synuclein
Objective/Rationale:
Clinical, genetic and experimental evidence supports an association between alpha-synuclein expression and Parkinson’s disease. This toxicity is likely to be attenuated by... -
Critical Challenges in PD: Translating Genetic Findings Into, 2007Dopamine Toxicity Hypothesis: Interaction with Alpha-Synuclein in the Intact Brain
Objective/Rationale:
Identification of mutations in the alpha-synuclein gene in a familial form of Parkinson’s disease, then the demonstration of alpha-synuclein containing pathological aggregations... -
Critical Challenges in PD: Translating Genetic Findings Into, 2007Elucidating the Role of Phosphorylation in modulating alpha-synuclein aggregation and toxicity in Parkinson's disease and related disorders
Objective/Rationale:
Chemical changes in the protein alpha-synuclein, such as the binding of phosphate groups (phosphorylation), are characteristic of Parkinson's disease and related alpha...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.